Yehuda Poliker Sparks Awareness as New Lung Disease Treatment Emerges

Singer Yehuda Poliker's public use of oxygen sheds light on advanced pulmonary fibrosis. As experts highlight new breakthroughs like nerandomilast, patients gain renewed hope.

Yehuda Poliker Sparks Awareness as New Lung Disease Treatment Emerges
Photo-illustration WireIsrael: AI Generated

Prominent Israeli singer Yehuda Poliker recently appeared on stage using supplemental oxygen, bringing visibility to pulmonary fibrosis, a severe and progressive lung disease. Poliker, who revealed that he is battling advanced pulmonary fibrosis, continues to perform despite facing debilitating breathlessness even after short walks. Pulmonologists have praised his openness, noting that his courage reduces stigma and offers vital hope to thousands of patients facing similar diagnoses.

A Decade of Waiting for a New Mechanism

Poliker's public disclosure coincided with significant medical advancements presented at the European Respiratory Society Congress in Barcelona. Medical professionals highlighted a novel therapeutic option known as nerandomilast, marketed under the name Jascayd. This medication represents the first pharmacological breakthrough with a new mechanism of action for pulmonary fibrosis in more than a decade. The drug specifically targets the PDE4B enzyme, which drives inflammation and scarring within lung tissue. It has already received regulatory approval in the United States and Europe for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, and has recently been approved for use in Israel.

Clinical trials demonstrated that the treatment successfully met its primary endpoints by significantly slowing the decline in pulmonary function compared to a placebo. Follow-up data spanning up to 76 weeks confirmed that the protective effect on lung capacity is sustained over time. Furthermore, the clinical trials observed a 49 percent reduction in the risk of mortality among progressive pulmonary fibrosis patients receiving the high dose compared to those on a placebo. Although the drug is approved in Israel, it is not yet included in the public health basket and is currently under review for inclusion in the 2027 healthcare services framework.

Tolerability and the Challenge of Side Effects

While older anti-fibrotic treatments introduced a decade ago successfully slow disease progression, many patients struggle to maintain their regimens due to severe adverse effects. Traditional medications frequently cause gastrointestinal distress, severe diarrhea, nausea, abdominal pain, and significant weight loss, leading discontinuation rates in real-world settings to reach up to 50 percent. In contrast, clinical trials for nerandomilast demonstrated a favorable safety profile with significantly lower discontinuation rates due to side effects, closely mirroring the placebo groups.

Specialists emphasize that a drug's theoretical efficacy is insufficient if patients cannot tolerate taking it consistently. The availability of a treatment that combines robust efficacy with high patient tolerability marks a critical turning point for individuals suffering from irreversible lung scarring. While the medication cannot reverse existing scar tissue or restore damaged lung elasticity, it provides an effective tool to preserve remaining respiratory function and maintain daily independence.

Early Symptoms and Diagnostic Delays

Pulmonary fibrosis involves the gradual thickening and stiffening of lung tissue, transforming flexible spongy organs into rigid structures that impair oxygen transfer into the bloodstream. Conditions include idiopathic pulmonary fibrosis, where the underlying cause remains unknown, as well as forms triggered by autoimmune diseases, environmental exposures, or occupational hazards such as inhaling silica dust during stone cutting. Early symptoms often mimic signs of aging or other conditions, including a persistent dry cough, progressive shortness of breath during exertion, fatigue, and unintended weight loss.

Because symptoms develop insidiously, patients frequently experience a diagnostic delay averaging about one year, often being evaluated first for cardiac conditions. Medical centers are increasingly adopting innovative diagnostic tools, such as artificial intelligence-driven software piloted at Sheba Medical Center to scan high-resolution computed tomography scans for interstitial lung abnormalities. Experts stress that recognizing symptoms early and seeking specialized pulmonary evaluation can prevent severe loss of lung function and dramatically improve overall quality of life.

Breaking the Stigma of Supplemental Oxygen

As the disease progresses, many patients eventually require supplemental oxygen to assist oxygenation, yet social stigma often causes individuals to hide their oxygen concentrators and avoid leaving home. Medical professionals view Poliker's public use of oxygen on stage as a watershed moment for patient advocacy, comparing the equipment to a necessary prosthetic limb that enables independence rather than something to conceal.

"I do not remember a singer performing on stage while relying on oxygen."

Although pulmonary fibrosis remains a serious condition requiring ongoing management, medical advancements and increased public awareness are transforming perceptions. The disease is gradually shifting from an untreatable diagnosis to a manageable condition, offering renewed optimism for thousands of patients across Israel.

Related News